Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies.

BACKGROUND

The unprecedented efficacy of chimeric antigen receptor T (CAR-T) cell immunotherapy of CD19 B-cell malignancies has opened a new and useful way for the treatment of malignant tumors. Nonetheless, there are still formidable challenges in the field of CAR-T cell therapy, such as the biodistribution of CAR-T cells in vivo.

METHODS

NALM-6, a human B-cell acute lymphoblastic leukemia (B-ALL) cell line, was used as target cells. CAR-T cells were injected into a mice model with or without target cells. Then we measured the distribution of CAR-T cells in mice. In addition, an exploratory clinical trial was conducted in 13 r/r B-cell non-Hodgkin lymphoma (B-NHL) patients, who received CAR-T cell infusion. The dynamic changes in patient blood parameters over time after infusion were detected by qPCR and flow cytometry.

RESULTS

CAR-T cells still proliferated over time after being infused into the mice without target cells within 2 weeks. However, CAR-T cells did not increase significantly in the presence of target cells within 2 weeks after infusion, but expanded at week 6. In the clinical trial, we found that CAR-T cells peaked at 7-21 days after infusion and lasted for 420 days in peripheral blood of patients. Simultaneously, mild side effects were observed, which could be effectively controlled within 2 months in these patients.

CONCLUSIONS

CAR-T cells can expand themselves with or without target cells in mice, and persist for a long time in NHL patients without serious side effects.

TRIAL REGISTRATION

The registration date of the clinical trial is May 17, 2018 and the trial registration numbers is NCT03528421 .